Sɔch fɔ di bɛst injɛkshɔn we de mek yu skin wayt ɛn yu go ɔltɛm mit di sem tri nem dɛn: glutathione, vitamin C (ascorbic acid) ɛn tranexamic acid (TXA). Bɔku tɛm di klinik dɛn kin prɛzɛnt dɛn lɛk 'braytin shot' we dɛn kin chenj, bɔt stil dɛn kin wok tru difrɛn we dɛn, dɛn kin gi dɛn difrɛn we dɛn ɛn dɛn kin kɛr rili difrɛn lɛvul dɛn fɔ pruf. So uswan de mek di skin brayt pas ɔlman? Di ɔnɛs ansa dipen pan di pigmɛnt prɔblɛm we dɛn de trit.
Insay dis atikul, 'brayt' min ivin aut tכn εn fεd εksyכs pigmεnt lεk melasma, san spat כ pכst-inflammatory mak dεm. I nɔ min fɔ chenj di pɔsin in natura l kɔlɔ we i gɛt frɔm in jɛnɛtiks, ɛn nɔbɔdi pan dɛn tin ya nɔ go ebul fɔ du dat fɔ ɔltɛm. Dɔŋ ya yu go si wan sayd-bay-sayd kɔmpiashɔn tebul, wan shɔt prɔfayl fɔ ɛni ingridiɛnt, wan disizhɔn gayd bay skin kɔnsyans ɛn di men sef ɛn rigyuletɔri pɔynt dɛn we klinik ɛn distribyushɔn fɔ no.
Glutathione vs Vitamin C vs Tranexamic Asid: Kɔmpiashɔn Tebul
Tin
Glutathione (GSH) we gɛt di sik.
Vitamin C (askɔbik asid) .
Tranexamik asid (TXA) we dɛn kɔl .
Men mɛkanism we dɛn kin yuz
Antiɔksidant tripɛptida; i de inhεbit tayrosinεz dayrekt εn indaykt εn i de shift melanin prodakshכn frכm dak yumelanin to layt faeomelanin
Antiɔksidant; inhεbit tayrosinεz bay we i de intarakt wit kכpa na di εnzym in aktv sayt, we de ridyus melanin fכmeshכn
Plasmin inhibitor we de mek pɔsin nɔ ebul fɔ du sɔntin; i de intarap di plasminogen–plasmin path we de lεnk di UV εkspכzכn εn di skin sεl dεm to melanosayt stimulashכn
Aw dɛn de yuz am
Ɔral kapsul ɔ lozenj, krim we dɛn kin put pan pɔsin; IV drip na pɔpul bɔt ɔf-lɛbul; sכmtεm dεn kin ad am to intradεmal mεsothεrapi kכktεl dεm
Di sɛrum dɛn we dɛn kin put pan pɔsin in bɔdi; intradεmal mεsothεrapi כ maykronidlin fכ pigmεnt; di hכy dכz IV infushכn dεm na sεparat, sεstεmik yus
Jɛnɛralized dullness ɛn antioxidant sɔpɔt, as ad-ɔn
dכl, fכto-dεmεj εn mild εpidamal pigmεnt; wan kɔmɔn patna to TXA
Melasma ɛn stɛp, ɔmon- ɔ UV-driven fes pigmɛnt
Kwaliti fɔ pruf
sכm sכm כral εn tכpikכl RCT dεm de sho mכdest melanin-indeks rεdukshכn; na wan wik plasɛbo-kɔntrol IV stɔdi nɔmɔ, we nɔ bin impɔtant
Smɔl trayal ɛn wan 2024 mɛta-analysis sho se mɛsotɛrapi wit vaytamɛn C de du di sem we lɛk TXA mɛsotɛrapi insay mɛlasma
Di wan we strɔng pas ɔl fɔ di tri fɔ melasma, pan ɔl we bɔku pan di injɛkshɔn stɔdi dɛn stil smɔl ɛn shɔt
Ki sefty not dɛn
IV yus we gɛt fɔ du wit di liva, kidni ɛn skin riakshɔn dɛn na di rɛgyulatɔ wɔnin; nɔ apruv IV dosing fɔ mek di skin layt
Yuz insay di bɔdi kin sting ɔ bɔn; di hεy dכz IV yus de kכri kidni-stכn εn G6PD-dεfisiεns kכnsεn
Di lokal rɛdnɛs, brus ɛn diskɔmfɔt; skrεnin fכ klot risk na standad prכsis bifo sistεmik yus
Tipik kɔmbaynshɔn dɛn
Ad to TXA + vaytamɛn C kɔktɛl dɛn
Pe wit TXA, wit ɔ atɔl glutathione
Base ingredient fɔ mɔs melasma kɔktɛl dɛn
Glutathione: Pɔpul, bɔt di Pruf Na Tin
Glutathione na nεchכral antioksidant we de insay kכlכsכl εvri sεl. rivyu dεn dεskrεb in laytin ifekt as i kכmכt frכm dayrekt εn indayrekt inhibishכn fכ tayrosinεz εn frכm swich melanin sεntez tכwεd layt pigmεnt (Sonthalia et al., 2016). Bɔt insay stɔdi dɛn we dɛn kin kɔntrol, di ifɛkt nɔ kin bɔku. Wan randomized, double-blind trial in 60 Thai volontia dɛn sho se 500 mg ɔral glutathione ɛvride fɔ 4 wiks ridyus melanin indices mɔ pas plasɛbo na tu pan siks sayt dɛn nɔmɔ (Arjinpathana ɛn Asawanonda). Wan opin-lɛbul stɔdi pan wan bukal lɔzɛn pan 30 Filipino uman dɛn bin ripɔt bak se di melanin indis dɛn de fɔdɔm, bɔt i nɔ bin gɛt ɛni plesibo grup (Handog et al., 2016).
Di pruf fɔ intravenɔs glutathione wik stil. Di onli plasεbo-kכntrol IV stכdi fכn no signifyant difrεns frכm salin (37.5% vs 18.7% improv, p = 0.054), di improvεmεnt fεd insay siks mכnt, εn sεvεra patisipan dεm bin gεt abnכmal liva tεst כ anafylaksis (Zubair et al., 2016). wan 2024 sistamat rivyu kכnklud se IV glutathione na kכntraindikεt fכ skin laytin εn se glutathione 'kin wok mכr as antioksidant insay melasma' (Sarkar et al.). Fɔ si bakgrɔn we fayn fɔ peshɛnt, si wi gayd fɔ aw glutathione skin wayt injɛkshɔn dɛn de wok.
Vitamin C: Di Antiɔksidant Patna
askorbik asid de nyutralayz fri radikal dεm we UV layt de mek εn i de inhεbit tayrosinase, we na di rizin we mek dεn bin de yuz am fכ lכng tεm fכ foto-ej εn haypapigmεntεshכn (Telang, 2013). di men wikɛd tin we i gɛt na di delivri: vaytamɛn C nɔ stebul ɛn i at fɔ go insay di dɛms pan yusful kɔnsɛntreshɔn, we de ɛksplen di intres pan mɛsotɛrapi ɛn maykronidling.
we dεn injεkt vaytam in C insay di dεm fכ melasma, i de ol in yon. Wan 2024 mεta-analysis fכ fayv stכdi (127 pasεnshכn) fכn no stεdi sכmtεm difrεns in MASI improvεmεnt bitwin TXA mεsothεrapi εn vaytam in C mεsothεrapi εn jכj כl tu fכ bi sef (Liao et al.). Di stɔdi dɛn bin smɔl, so i bɛtɛ fɔ rid dis as 'kɔmparabl insay limited data' pas pruf fɔ ikwal.
Tranexamic Acid: Di Mɛlaasma Spɛshal
Dɛn bin mek tranexamic acid as mɛrɛsin fɔ ridyus blɔd. di rol we i de ple na di pigmεnt de kכmכt frכm fכ blכk di plasmin aktiviti, we na wan path we de involv insay UV-trigεr melanosayt aktibכshכn. Insay di fɔs intradɛm stɔdi, 85 Korian uman dɛn bin gɛt 4 mg/mL maykroinjɛkshɔn ɛvri wik insay mɛlasma lɛshɔn fɔ 12 wik; di min MASI skכl fכl frכm 13.22 to 7.57 wit minimכl sayd ifekt (Lee et al., 2006). Da stɔdi de nɔ bin gɛt ɛni kɔntrol grup. Wan leta randomized trial in 60 pasɛnt dɛn fɛn 35.72% MASI improvement wit TXA maykroinjɛkshɔn ɛn 44.41% wit TXA we dɛn deliv bay maykronidling, wit nɔ big advays ivin (Budamakuntla et al., 2013).
Di ditel dɛm fɔ di protɔkɔl, di intaval dɛm fɔ di sɛshɔn ɛn di sɛlɛkshɔn fɔ di pɔsin we sik de insay wi dediket atikul bɔt tranexamic acid mesotherapy fɔ melasma , so wi nɔ go ripit dɛn ya.
Uswan Na di Bɛst? Wan Disishɔn Gayd bay Skin Kɔnsɔn
No wan bɛst injɛkshɔn nɔ de fɔ mek pɔsin wayt. Di rayt tin fɔ pik na fɔ fala di diagnosis:
Melasma we gɛt di sik
TXA na di fכs ingridiεnt we mכst dεmatכlכg dεm de rich fכ, dεn de gi am insay dεm כ wit maykronidling, nia strikt san protεkshכn. Vitamin C mesotherapy na rizin ɔltɛrnativ ɔ patna, we dɛn gi di kɔmparabl rizɔlt dɛn na di mɛta-analysis. Glutathione na opshɔnal ad-ɔn, nɔto wan stand-alɔn ansa.
Oval dullness ɛn nɔ ivin tɔyn
Fɔ taya, salɔ ɔ foto-damɛj skin we nɔ gɛt difayn pigmɛnt dizayd, antiɔksidant sɔpɔt impɔtant pas ɔl. Vitamin C na di lכjik kכr, εn glutathione kin kכntribyut antioksidant bεnεfit. di ekspekteshכn dεm fכ fram as 'fresh, mכr ivin skin', nכto layt kכmpleks.
Pɔst-inflammatory haypapigmɛnt (PIH) .
Mak dɛm we lɛf afta akni ɔ iritashɔn kin dɔn wit tɛm, san protɛkshɔn ɛn saful saful topikal kia. If dɛn yuz injɛkshɔn, di prɔtokɔlɔ dɛn we nɔ gɛt bɛtɛ iritashɔn wit vaytamɛn C ɔ TXA mek sɛns, bikɔs agresiv tritmɛnt kin mek nyu pigmɛnt. Wi ɔvaviu fɔ injεkshכn dεm we de mek di skin brayt fכ haypa pigmεnt de εksplen di men kayn pigmεnt dεm mכr ditayli.
Antioksidant sɔpɔt arawnd ɔda prɔsidyu dɛm
Bɔku tɛm dɛn kin pik di vitamin C ɛn glutathione as sɔpɔt ingridiɛnt dɛn we de rawnd laser ɔ peel. Dɛn nɔ de tek ples fɔ wan tritmɛnt plan we gɛt fɔ du wit di pigmɛnt.
Kɔmbayn Fɔmula: Wetin Mek Bɔku Klinik dɛn De Yuz Ɔl di Tri
biכs di tri ingridiεnt dεm de akt pan difrεn stεp dεm fכ fכm di pigmεnt, di mכdan brayt fכmula dεm kin kכmbayn TXA, vaytam in C εn glutathione pas fכ pik wan. Klinik data de sɔpɔt dis lɔjik, at ɔl insay smɔl smɔl trayal dɛn. Insay wan dabl-blaynd, split-fes trayal fɔ 24 melasma pasɛnt dɛn, TXA plus askɔbik asid bin lɔs MASI skɔ mɔ pas TXA plus plasɛbo na wik 8 ɛn 12, pan ɔl we pen we dɛn de bɔn bin notis mɔ na di kɔmbayn sayd (Pazyar et al., 2022). Insay wan ɔda split-fes trayal pan 30 pasɛnt dɛn, wan kɔktɛl we gɛt TXA 4 mg/mL, vaytamɛn C 3% ɛn glutathione 2% ridyus mMASI mɔ pas TXA ɛn vaytamɛn C nɔmɔ, wit di sem kayn rit fɔ rɛdnɛs, swel ɛn brus (Iraji ɛn ɔda pipul dɛn, 2019).
IV glutathione nɔto wan mɛrɛsin we dɛn dɔn gri fɔ fɔ mek di skin wayt na bɔku makit dɛn. Insay in 2019 advayz, di Filipin FDA bin tɔk se dɛn nɔ bin gri fɔ ɛni injɛkshɔn prodak fɔ mek di skin layt, dɛn bin gri fɔ injɛkt glutathione jɔs as adjɔnt fɔ cisplatin kemotɛrapi, ɛn dɛn bin wɔn bɔt pɔsibul liva, kidni ɛn nervɔs-sistim ifɛkt ɛn Stivins-Jɔnsin sindrom.
Di ay doz IV vaytamɛn C kin kɛr in yon risk dɛn. Di sem advays bin notis se vaytamɛn C injɛkshɔn kin mek kidni ston ɛn big dos dɔn mek dɛn gɛt ɛmodayalis pan pipul dɛn we nɔ gɛt G6PD.
Lokal injɛkshɔn nɔ kin gɛt risk. Ekspekt fɔ rɛd, sting, swel ɔ brus fɔ shɔt tɛm. Sterile teknik ɛn kɔrɛkt dip impɔtant.
Rizult nɔto fɔ ɔltɛm. di pigmεnt de kam bak if di UV εksposhכn, כmon כ inflameshn de kכntinyu. Ɛvride brayt-spɛktrum san protɛkshɔn na pat pan ɛvri protɔkol.
No di lɔ dɛn we de na yu eria. Di prodak rɛjista ɛn udat kin injɛkt difrɛn bay kɔntri. Na pipul dɛn we sabi du di wok fɔ gi di tritmɛnt ɛn gi am.
Fɔ Klinik ɛn Distributɔ dɛn
Klinik dɛn kin si bɛtɛ autkam ɛn smɔl kɔmplen we dɛn no di kayn pigmɛnt fɔs, pik TXA-based protɔkɔl fɔ melasma ɛn prɛzɛnt glutathione ɔnɛs wan as antiɔksidant adjɔnt pas fɔ chenj di skin-kɔlɔ. Di wan dɛn we de sheb di prɔdak fɔ chɛk if ɛni prɔdak in rɛjista ɛn lɛbl fit dɛn target makit.
AOMA de mek brayt mɛsotɛrapi sɔlvishɔn, inklud TXA, vaytamɛn C ɛn kɔmbayn fɔmula, fɔ stok saplai ɛn OEM. Yu kin browz di AOMA skin waytin injεkshכn rεnj . Di MOQ stat frɔm 200 yunit fɔ ɔl tu di stok ɛn OEM ɔda dɛn. Stock oda ship insaid 24 awa, en OEM lida taim na 2–3 wiks afta artwok, fomula en pak ditel dem konfam. AOMA gɛt CE, ISO 13485, GMP ɛn FDA sɛtifiket dɛn.
FAQ we dɛn kin aks
Wetin na di bɛst injɛkshɔn we de mek pɔsin wayt?
No wan pɔsin nɔ de we win. fכ melasma, tranexamic acid gεt di mכst sכpכt injεkshכn data. Fɔ jenɛral dɔl, vaytamɛn C na sɛnsful antiɔksidant chuk. Glutathione na men wan we dɛn kin ad. Wan dɔktɔ fɔ no di prɔblɛm we de wit di pigmɛnt bifo i pik.
Glutathione bɛtɛ pas vaytamɛn C fɔ mek di skin brayt?
Nɔto klia wan. Dɛn ɔl tu gɛt smɔl pruf nɔmɔ we nɔ go te, ɛn we go de fɔ shɔt tɛm. Vitamin C gɛt mɔ injɛkshɔn data fɔ melasma, we IV glutathione nɔ ebul fɔ bit plasɛbo insay in wan kɔntrol trayal.
Yu tink se dɛn kin injɛkt tranexamic acid, vaytamɛn C ɛn glutathione togɛda?
Yes, kɔmbayn kɔktɛl na kɔmɔn tin, ɛn smɔl split-fes trayal dɛn sho se we dɛn ad vaytamɛn C, ɛn afta dat glutathione, to TXA, dat kin mek di melasma skɔ dɛn bɛtɛ. Bɔn ɔ sting kin bɔku wit di kɔmbaynshɔn.
Yu tink se di injɛkshɔn dɛn we dɛn kin yuz fɔ mek yu wayt kin chenj di kɔlɔ fɔ di skin fɔ ɔltɛm?
Nɔ, dɛn kin mek di pigmɛnt we pasmak nɔ de igen ɛn ivin di tɔyn we de kɔmɔt na di bɔdi, bɔt dɛn nɔ kin chenj di natura skin kɔlɔ, ɛn di tin dɛn we kin kɔmɔt de kin fayn if dɛn nɔ protɛkt dɛn frɔm di san ɛn mek dɛn kɔntinyu fɔ gɛt am.
IV glutathione sef fɔ mek yu skin wayt?
Rigyulatɔ dɛn lɛk di Filipin FDA dɔn wɔn am agens am, ɛn wan 2024 sistamɛtik rivyu bin tek IV glutathione nɔ fɔ mek di skin layt bikɔs i nɔ de wok fayn ɛn i nɔ gɛt ɛni sayd ɛfɛkt.
Rifrɛns dɛn
Lee JH, Park JG, Lim S. H., ɛn ɔda pipul dɛn. Lokal intradεmal maykroinjεkshכn fכ tranexamic asid fכ trit mεlasma in Eshian pasεnshכn dεm: wan prεliminεri klinik trial. Dɛrmatol Surg . 2006;32(5):626-631. PMID: 16706756, ɛn di ɔda wan dɛn.
Budamakuntla L, Loganathan E, Suresh D. H., ɛn ɔda pipul dɛn. Wan randomiz, opin-lɛbul, kɔmparativ stɔdi fɔ tranexamic asid maykroinjɛkshɔn ɛn tranexamic asid wit maykronidling insay pasɛnt dɛn we gɛt mɛlasma. J Kutan Aesthet Surg . 2013;6(3):139–143. PMID: 24163529, ɛn di ɔda wan dɛn.
Liao X, Cheng F, Jiang Y. Efikεsi εn sef fכ mεsothεrapi wit tranexamic asid vεrs vaytam in C in di tritmεnt fכ melasma: wan mεta-analysis εn sεstεmik rivyu. J Kosmet Dɛrmatol . 2024;23(9):2785-2792. PMID: 38693699, ɛn di ɔda wan dɛn.
Pazyar N, Molavi S. N., Hosseinpour P, ɛn ɔda pipul dɛn. Efikכs fכ intradεmal injεkshכn fכ tranexamic asid εn askorbik asid vεrs tranexamic asid εn plasεbo in di tritmεnt fכ melasma: wan split-fes kכmparativ trayal. Wɛlbɔdi Sayɛns Rip . 2022;5(2):e537. PMID: 35284654, ɛn di ɔda wan dɛn.
Iraji F, Nasimi M, Asilian A, ɛn ɔda pipul dɛn. Efikכs fכ mεsothεrapi wit tranexamic asid εn askorbik asid wit εn witout glutathione in tritmεnt fכ melasma: wan split fes kכmparativ trayal. J Kosmet Dɛrmatol . 2019;18(5):1416-1421. PMID: 30735611, ɛn di ɔda wan dɛn.
Sonthalia S, Daulatabad D, Sarkar R. Glutathione as wan skin waytin ejen: fakt, lay lay stori, pruf ɛn kɔntroversi. Indian J Dɛrmatɔl Vɛnɛriɔl Lɛprɔl . 2016;82 (3):262-272. PMID: 27088927, ɛn di ɔda wan dɛn.
Sarkar R, Yadav V, Yadav T, ɛn ɔda pipul dɛn. Glutathione as wan skin-laytin ejen ɛn insay melasma: wan sistamɛtik rivyu. Int J Dɛrmatɔl . 2025;64(6):992–1004 (ɔnlayn 2024). PMID: 39444151, ɛn di ɔda wan dɛn.
Arjinpathana N, Asawanonda P. Glutathione as wan ɔral waytinin ɛjɛn: wan randomiz, dɛbul-blaynd, plesibo-kɔntroled stɔdi. J Dɛmatɔlɔjik Trit . 2012;23(2):97-102. PMID: 20524875, ɛn di ɔda wan dɛn.
Handog E. B., Datuin M. S., Singzon I. A., ɛn ɔda pipul dɛn. Wan opin-lɛbul, singl-am trayal fɔ di sef ɛn ɛfifikɛshɔn fɔ wan nyu prɛparashɔn fɔ glutathione as skin-laytin ɛjɛn na Filipino uman dɛn. Int J Dɛrmatɔl . 2016;55(2):153-157. PMID: 26148180, ɛn di ɔda wan dɛn.
Zubair S, Hafeez S, Mujtaba G. Efikεsi כf intravenכs glutathione vs. plasεbo fכ skin tכn laytin. J Pak Assoc Dɛrmatol . 2016;26(3):177. https://jpad.com.pk/index.php/jpad/atikul/viu/18. Di wan dɛn we de stɔdi bɔt di Baybul
Telang PS. Vitamin C insay dɛmatɔlɔji. Indian Dɛrmatɔl Ɔnlayn J . 2013;4(2):143-146. PMID: 23741676, ɛn di ɔda wan dɛn.
Fɔd ɛn Drug Administreshɔn Filipins. FDA Advayz Nɔmba 2019-182: Yuz glutathione we nɔ sef as ejen fɔ layt di skin. 2019. https://www.fda.gov.ph/fda-advayz-nɔ-2019-182-nɔ-sef-yuz-ɔf-glutathione-as-skin-laytin-ejɛnt/
Dis atikul na fɔ tich pipul dɛn nɔmɔ ɛn nɔto dɔktɔ advays. Di tritmɛnt dɛn we dɛn kin yuz fɔ mek pɔsin brayt brayt wan we dɛn kin injɛkt fɔ asɛs ɛn du am bay kwalifay prɛktishɔn dɛn we de fala di lokal rigyuleshɔn dɛn.
Dr. Emily Carter (MD, Fellow of the American Academy of Dermatology) na bɔd-sɛtifiket kɔsmɛtik sajin na Nyu Yɔk Siti wit pas 9 ia spɛshal ɛkspiriɛns pan hyaluronic acid filers, akni ska tritmɛnt, ɛn minimally invasive facial contouring. Dɛn no am mɔ fɔ in ɛkspɛriɛns pan advans injɛkshɔn tritmɛnt dɛn we de mek di akni ska dɛn layt fayn fayn wan, mek di skin wɛl, ɛn mek di skin smol bak tru di injɛkshɔn we dɛn dɔn tɔk bɔt fɔ mek di skin ripɛnt ɛn di tɛknik dɛn we dɛn de yuz fɔ mek di skin go bifo.
